

# AnteoTech Ltd

## Managing Director AGM Presentation

**BRISBANE, AUSTRALIA, 26 November 2024:** AnteoTech Ltd (ASX:ADO) will today present the attached presentation at its Annual General Meeting. A copy of the Managing Director's presentation is attached.

This announcement has been authorised for release by the Board of AnteoTech Ltd.

- ENDS -

**Media and investor enquiries:** +61 7 3219 0085 or [investors@anteotech.com](mailto:investors@anteotech.com)

**Company and Partnering enquiries:** David Radford, CEO, on + 61 7 3219 0085

For further information, please check our website [www.anteotech.com](http://www.anteotech.com)

### About AnteoTech - (ASX:ADO)

AnteoTech is a revenue-stage company that provides solutions for the clean energy and life sciences markets using our proprietary applied materials technology. In the rapidly growing clean energy market, our lead product Anteo X™, has been proven to provide significant improvement in anode performance and the Company has partnered with global suppliers to the lithium-ion battery manufacturing industry. The portfolio includes a proprietary high silicon anode, made with unrefined silicon which offers advantages of size, weight and cost. The Life Sciences division services the Point-of-Care and In vitro diagnostics markets; from global diagnostics companies to technology developers. The unique characteristics of AnteoBind™ provides strong advantages in bioconjugation to rapidly speed up testing procedures and improve accuracy.

### AnteoTech - Social Media Policy

AnteoTech is committed to communicating with the investment community through all available channels. Whilst ASX remains the prime channel for market sensitive news, investors and other interested parties are encouraged to follow AnteoTech on LinkedIn. Subscribe to AnteoTech Latest News emails - visit our website at [www.anteotech.com](http://www.anteotech.com) and subscribe to receive our email alert service.

### Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates and Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target", "outlook", "guidance" and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of AnteoTech. The Estimates and Projections are based on information available to AnteoTech as at the date of the Announcement, are based upon management's current expectations, estimates, projections, assumptions and beliefs in regards to future events in respect to AnteoTech' business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of AnteoTech and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by AnteoTech in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. AnteoTech takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.

# 2024 Annual General Meeting

David Radford

Managing Director Presentation



# IMPORTANT NOTICE



## SCOPE & LIMITATIONS

This Presentation has been prepared by AnteoTech Ltd (**AnteoTech** or the **Company**) (ASX:ADO). The Presentation is a summary only and does not contain all the information about the Company's assets and liabilities, financial position and performance, profits and losses and prospects. This material in this Presentation may be supplemented with an oral presentation and/or other more detailed documents and should not be taken out of context. Although the information contained herein is based upon generally available information and has been obtained from third-party sources believed to be reliable, the Company does not guarantee its accuracy, and such information may be incomplete or condensed. The Company also refers to its filings made with the ASX Limited and the Australian Securities & Investments Commission.

## FORWARD LOOKING INFORMATION

This Presentation contains forward looking and other subjective information. Such expectations, estimates, projections and information are not a guarantee of future performance and involve unknown risks and uncertainties. Actual results and developments will almost certainly differ from those expressed or implied and recipients of this Presentation should make their own assessment of the expectations, estimates, projections and the relevant assumptions and calculations upon which the opinions, estimates and projections are based. No representation or warranty, express or implied, is given as to the accuracy or completeness of the information or opinions contained in this Presentation and no liability whatsoever is accepted by the Company, or its directors, members, officers, employees, agents or advisers for any use or, or reliance placed upon, such information or opinions.

## NOT AN OFFER FOR SECURITIES

This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any shares nor does it constitute financial product or investment advice nor take into account your investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this Presentation but must make its own assessment of the Company and conduct its own investigations and analysis. Before making an investment in the Company, a prospective investor should consider whether such an investment is appropriate to their particular investment objectives and financial situation and seek appropriate advice, including legal, taxation and financial advice appropriate to their jurisdiction and circumstances.

## UNITED STATES

The Company's securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the Securities Act), or under the securities laws of any state or other jurisdiction of the United States. Accordingly, the Company's securities may not be offered or sold, directly or indirectly, within the United States or to, or for the account of benefit of, U.S. Persons (as defined in Regulation S under the Securities Act as amended). This Presentation may not be distributed within the United States or to any person in the United States.

## OTHER JURISDICTIONS

This Presentation may only be accessed in other jurisdictions where it is legal to do so.

THIS PRESENTATION HAS BEEN APPROVED BY THE BOARD OF ANTEOTECH LTD

CREATING VALUE BY THE  
ACCELERATED DEVELOPMENT  
AND COMMERCIALISATION OF  
SOCIETALLY BENEFICIAL  
SOLUTIONS BY OUR  
INNOVATIVE TECHNOLOGY  
AND PASSIONATE TEAM



# The foundation for the Commercial journey

**Financial Year 2024**

# DELIVERING ON COMMITMENTS

Commercial and technical achievements position AnteoTech for near term partnering and revenue opportunities

## Clean Energy



**Testing Prototype with Anteo X™**  
Mercedes Benz



**Anteo X™ Cycle Milestone**  
1000+ cycles, >70% retention



**First CET Revenues**  
Optimised anode sold to Mercedes Benz



**First Commercial Sales**  
Ultranode™ - 70% silicon



**Production Facility Complete**  
On time and budget



**Expanding Sales Team**  
VP International Sales + 3 PDMs

## Life Sciences



**US\$1.8m 5-year Agreement**  
World's largest vaccine manufacturer



**AnteoBind NXT Launched**  
Major benefits in activation



**AnteoBind NXT Evaluation**  
Vidcare targeting product release 2025

## Corporate



**Operational Overhaul**  
Commercial ready - \$3.3m costs saved



**One off Issues Resolved**  
Ferroglobe + EUGENI project




**Two grants - \$5.4m Committed**  
Funds Ultranode™ development

# ANTEO X™ – 20% SILICON - HIGH PERFORMANCE ANODES



Compelling performance data generated – multiple commercial evaluations of Anteo X™ technology



## Anteo X™ Features

- High performance anode with 20% silicon
- Increased energy capacity and cycle life
- Decreased costs
- Ease of incorporation



## Customer Benefits


- ✓ Slimmer anodes
- ✓ Greater energy for reduced cost
- ✓ Cycle life matches existing technology
- ✓ Transition costs reduced

## Consumer Benefits

- Si Faster charging – ease of use
- Si Reduction in range anxiety
- Si 1000 cycles = 300,000 km over life of battery

# ULTRANODE™ – OVER 70% SILICON - NEXT GEN ANODES

Increasing Energy capacity & cycle life demonstrates the technical capabilities of the team



## Ultranode™ Features

- Ultra-high 70% silicon anode
- Increased energy capacity and cycle life
- Decreased costs
- Currently achieving 900 cycles @ 70% energy retention



ULTRANODE

## Customer Benefits

- ✓ Slimmer anodes
- ✓ Very high energy anodes
- ✓ Low-cost silicon materials
- ✓ Validated manufacturability

## Consumer Benefits


- Si Faster charging – ease of use
- Si Reduction in range anxiety
- Si 1000 cycles = 300,000 km over life of battery



# ANTEOBIND™ – DATA QUANTIFYING BENEFITS

New data supports lower manufacturing cost and cheaper affordable diagnostic tests

## AnteoBind NXT achieves significant cost savings vs. EDC/sNHS



## AnteoBind™ NXT - Features

- Versatile, works on different particles size, type and manufacturers
- Works on lateral flow and chemiluminescence platforms
- Lower conjugate manufacturing cost – less antibodies and AnteoBind NXT



## Customer Benefits

- ✓ Lower cost to manufacture
- ✓ Increased margins-quality and cost reductions
- ✓ Ease of use driving efficiency of manufacture

## Consumer Benefits

- ⊕ Enhanced sensitivity improves test accuracy and customer confidence
- ⊕ Affordable diagnostic tests for customers

# NON-DILUTIVE FUNDING - \$4M ARENA GRANT


Major validation by this Australian government agency



**\$3.99m funding grant**  
– non dilutive matched funding & no IP rights



**Independent technical analysis by ARENA**



**Commercialising Ultra High Silicon Anode  
capable of >1000 cycles at 80% capacity**

## Joint media release: \$4 million to drive Australian battery innovation

29 October 2024

The Hon Chris Bowen MP, Minister for Climate Change and Energy

The Hon Ed Husic MP, Minister for Science and Industry

Through the Australian Renewable Energy Agency (ARENA), the government is investing \$4 million to support new silicon anode technology that gives lithium-ion batteries much higher energy density. This higher energy density means future batteries could supply the same amount of power while being smaller, lighter and cheaper.

The government's investment will support Australian company AnteoTech's \$11.1 million project to bring its commercial technology to market. The global demand for lithium-ion batteries is expected to ramp up from 700 GWh of annual demand in 2022 to around 4,700 GWh by 2030 – mainly due to EVs.

**Minister for Climate Change and Energy, Chris Bowen, said** Australian innovation was delivering better batteries that could help electrify homes and cars across the world.

*"We're investing in home-grown technology that has the potential to drive down the cost of batteries and make them more efficient,"*

Minister Bowen said. *"If the project is successful, it would help extend the range of electric cars and reduce the costs and size of home batteries."*

**Minister for Industry and Science, Ed Husic, said** Australia is a pioneer in battery tech, keeping our smarts onshore will create more well-paid secure jobs.

*"With the global demand for batteries set to grow six-fold by 2030, Australia must be a player in this field."*

*"We've got a once-in-a-lifetime opportunity for Australia to scale-up battery manufacture in Australia and take advantage of the global transition to net zero,"*  
Minister Husic said.

# BUILDING OUR BALANCE SHEET

New institutional shareholders joined the register

## Funding our Development

Placement - completed

**\$3.5m**

Entitlement Offer – [Open](#)

**1 for 10**

- Offer closes 9 Dec 24
- Shareholders at 18 Nov 24
- Directors participating
- Ability to apply for shortfall - up to 500% of entitlement
- Refer to Entitlement Offer Booklet released 21 Nov 2024



<sup>1</sup> Closing share price on 19 Nov 2024

<sup>2</sup> 22 November 2024 cash balance, R&D Tax Rebate and Placement proceeds

<sup>3</sup> Cash balance as defined above, and proceeds from Entitlement Offer (after costs) assuming full take-up

Market Capitalisation<sup>1</sup>

**\$56.0m**

Cash<sup>2</sup>

**\$7.2m**

Pro Forma Cash<sup>3</sup>

**\$11.8m**

Debt

**Nil**

# CY2025 & Beyond



# GOALS FOR SUCCESS IN CY2025

Strategies to build on our commercial momentum – driving revenues and partnerships in CY2025

1

Delivering multiple revenue streams and agreements - diversification

2

Advancing our targeted high value clean energy customers - validation

3

Building revenues from our key Indian life sciences customers - delivery


4

Prudent capital management & partnerships - execution



# DIVERSE REVENUE STREAMS

Product sales – Paid development activities – Partnering opportunities



# CLEAN ENERGY – CY2025 CURRENT OPPORTUNITIES

Key targets to building revenue for Anteo X™ and Ultranode™



## Electric Vehicles

### Mercedes-Benz

→ Support ongoing evaluation of Anteo X™ and Ultranode™

→ JDA Ultranode™ – Target 2H 25

→ Anteo X™ sales for next gen. batteries

### EV2

→ Anode JDA – Target 2H 25

### EV3

→ Target anode development program – 1H 25



## Advanced Chemistries

### Separator Technology

→ Confirm Anteo X™ reduces shrinkage > safer batteries

→ Target commercial agreement for Anteo X™

### Carbon Nano Tubes

→ Confirm Anteo X™ delivers expected performance improvements

→ Commercial agreement to develop enhanced products with Anteo X™

→ Enter USA via leading CNT company



## Consumer & Medical

### Wyon

→ Leverage recent visit and move to sales of 70% Ultranode™

### Consumer Battery

→ Commercial agreement in US for mobile phone batteries

→ Development agreement with niche high performance battery company

→ Leverage Intl Sales Directors relationships across the industry

# LIFE SCIENCES – CY2025 CURRENT OPPORTUNITIES



Building revenue streams for AnteoBind and AnteoBind NXT



**US\$1.8m min.** Purchase Agreement – 5 years

- Continue to expand usage in current vaccine program QA
- Expand into new vaccine development programs
- Expand relationship through assay development services
- Explore growth in SII-Lateral flow and other diagnostic tests



Evaluation underway – **performance evidenced**

- Complete validation of AnteoBind NXT in the initial PoC test for India
- Enter into commercial agreement
- Expand into tests currently being considered including consumer PoC tests for European market

## Business Development Targets

Reduction in antibody usage is of value to key diagnostics companies

- Targeted promotions leveraging the enhanced data sets to drive engagement with new diagnostic customers
- Targeted strategy for new Indian PoC companies
- Leverage Indian government “Health for All” initiatives

# FIVE KEY TAKEAWAYS

**1**

## **Two next generation battery products – new and compelling data**

Two evaluations with Mercedes on path to JDA – evaluations with other leading companies across battery sector

**2**

## **Clean energy revenues – platform for sales and growth**

Production Facility commissioned – Technical team in place to support customer requirements

**3**

## **US\$1.8m life sciences revenues locked in – world's largest vaccine manufacturer**

Expanding use cases to build long term revenues – Completing validation with Vidcare to launch tests across India from 2025

**4**

## **Operations overhauled for commercial success**

Placement builds balance sheet to support 2025 initiatives – launched Entitlement Offer to current shareholders

**5**

## **Multiple commercial milestones in 2025**

Agreements - Sales of products – Paid development activities – Partnering opportunities

